The therapeutic time window-theoretical and practical considerations

Journal of Stroke and Cerebrovascular Diseases

Volumn 9, Issue 6, 2000, Pages 24-31

  Hsu, Chung Y ^a,b   Ahmed, S Hinan ^a,b   Lees, Kennedy R ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

Clinical trials; Clomethiazole; Neuroprotectants; Stroke

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; APTIGANEL; BASIC FIBROBLAST GROWTH FACTOR; CASPASE; CASPASE INHIBITOR; CITICOLINE; CLOMETHIAZOLE; EBSELEN; ELIPRODIL; FLUNARIZINE; FOSPHENYTOIN SODIUM; GANGLIOSIDE GM1; GAVESTINEL; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; LUBELUZOLE; MAGNESIUM; NALMEFENE; NEUROPROTECTIVE AGENT; NIMODIPINE; PIRACETAM; TIRILAZAD;

APOPTOSIS; BLOOD PRESSURE; BRAIN INJURY; BRAIN PROTECTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG INFUSION; GLUCOSE BLOOD LEVEL; HUMAN; NEUROPROTECTION; NURSING; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0033653705     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1053/jscd.2000.19318     Document Type: Review

References (81)

1. Transient forebrain ischemia of three-minute duration consistently induces severe neuronal damage in field CA1 of the hippocampus in the normothermic gerbil
2. Temporal thresholds for neocortical infarction in rats subjected to reversible focal cerebral ischemia
3. Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats
4. Long-lasting neuroprotective effect of postischemic hypothermia and treatment with an anti-inflammatory/antipyretic drug: Evidence for chronic encephalopathic processes following ischemia
5. Mechanisms of secondary brain injury
6. Very delayed infarction after mild focal cerebral ischemia: A role for apoptosis?
7. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family
8. Histopathologic clues to the pathways of neuronal death following ischemia/hypoxia
9. The ischemic penumbra, injury thresholds, and the therapeutic window for acute stroke
10. Factors determining the therapeutic window for stroke
11. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death
12. Neuroprotective effects of lamotrigine enhanced by flunarizine in gerbil global ischemia
13. Ischemic cell death in brain neurons
14. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat
15. The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat
16. The neuroprotective effect of the novel AMPA receptor antagonist PD152247 (PNQX) in temporary focal ischemia in the rat
17. Delayed treatment with dextromethorphan and dextrorphan reduces cerebral damage after transient focal ischemia
18. A dose-response study of dextrorphan in permanent focal ischemia
19. Induction of Krox-20 expression after focal cerebral ischemia
20. Expression of c-fos and c-jun family genes after focal cerebral ischemia
21. Immediate early gene expression in response to cerebral ischemia. Friend or foe?
22. Basic fibroblast growth factor protects against hypoxia-ischemia and NMDA neurotoxicity in neonatal rats
23. Amelioration of delayed neuronal death in the hippocampus by nerve growth factor
24. Transforming growth factor-beta 1 prevents glutamate neurotoxicity in rat neocortical cultures and protects mouse neocortex from ischemic injury in vivo
25. The window of opportunity for neuronal rescue with insulin-like growth factor-1 after hypoxia-ischemia in rats is critically modulated by cerebral temperature during recovery
26. Growth factors and brain injury
27. Neurotrophic factors
28. Neocortical neural sprouting, synaptogenesis, and behavioral recovery after neocortical infarction in rats
29. Intracisternal basic fibroblast growth factor (bFGF) enhances behavioral recovery following focal cerebral infarction in the rat
30. Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction
31. Role of oxidants in ischemic brain damage
32. Inflammatory mediators and stroke: New opportunities for novel therapeutics
33. Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat)
34. Cytokines, macrophages, and leukocytes in brain ischemia
35. Delayed treatment with aminoguanidine decreases focal cerebral ischemic damage and enhances neurologic recovery in rats
36. Role of nerve growth factor in a mouse model of allergic airway inflammation and asthma
37. Cellular sources of enhanced brain-derived neurotrophic factor production in a mouse model of allergic inflammation
38. Gene expression induced by cerebral ischemia: An apoptotic perspective
39. Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: A perspective on the contributions of apoptosis and necrosis
40. Electron microscopic evidence against apoptosis as the mechanism of neuronal death in global ischemia
41. Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia
42. Caspase-8 and caspase-3 are expressed by different populations of cortical neurons undergoing delayed cell death after focal stroke in the rat
43. Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury
44. Caspases as treatment targets in stroke and neurodegenerative diseases
45. Suppression of postischemic hippocampal nerve growth factor expression by a c-fos antisense oligodeoxynucleotide
46. N-methyl-D-aspartate receptor-mediated neuroprotection in cerebellar granule cells requires new RNA and protein synthesis
47. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury: Results of the Second National Acute Spinal Cord Injury Study
48. Effects of timing of methylprednisolone or naloxone administration on recovery of segmental and long-tract neurological function in NAS-CIS 2
49. Dose escalation safety and tolerance study of the competitive NMDA antagonist selfotel (CGS 19755) in neurosurgery patients
50. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke: Results of a phase IIa randomized trial
51. In vivo distribution of CGS-19755 within brain in a model of focal cerebral ischemia
52. Blood glucose, glycosylated hemoglobin, and outcome of ischemic brain infarction
53. Is hyperglycaemia an independent predictor of poor outcome after acute stroke?
54. Relation of hyperglycemia early in the ischemic brain infarction to cerebral anatomy, metabolism, and clinical outcome
55. Clinical utility of diffusion-weighted magnetic resonance imaging in the assessment of ischemic stroke
56. Regional ischemia and ischemic injury in patients with acute middle cerebral artery stroke as defined by early diffusion-weighted and perfusion-weighted MRI
57. The ischemic penumbra: Operationally defined by diffusion and perfusion MRI
58. New magnetic resonance imaging techniques for stroke diagnosis and treatment
59. Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke
60. Cervene in acute ischemic stroke: Results of a double-blinded, placebo-controlled, dose-comparison study
61. A randomized efficacy trial of citicoline in patients with acute ischemic stroke
62. Effect of citicoline on ischemic lesions as measured by diffusion-weighted MRI
63. Clomethiazole acute stroke study (CLASS): Results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients
64. Ebselen in acute ischemic stroke: A placebo-controlled, double-blind clinical trial
65. Flunarizine in stroke treatment (FIST): A double-blind, placebo-controlled trial in Scandinavia and the Netherlands
66. Ischemic brain injury and the therapeutic window
67. Early treatment of stroke with monosialoganglioside GM-1: Efficacy and safety results of the Early Stroke Trial
68. Ganglioside GM1 in acute ischemic stroke: The SASS Trial
69. Efficacy and safety of GV150526 in acute stroke: Results of the GAIN Americas trial (Glycine antagonist in neuroprotection)
70. Phase II studies of the glycine antagonist GV150526 in acute stroke: The North American experience
71. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: A randomised controlled trial
72. Lubeluzole in acute ischemic stroke: A double-blind, placebo-controlled phase II trial
73. Lubeluzole treatment of acute ischemic stroke: The US and Canadian Lubeluzole Ischemic Stroke Study Group
74. VENUS: Very early nimodipine use in stroke: Preliminary trial results
75. Randomised, double-blind, placebo-controlled trial of nimodipine in acute stroke
76. Clinical trial of nimodipine in acute ischemic stroke
77. Treatment of acute ischemic stroke with piracetam
78. Termination of Acute Stroke Studies Involving Selfotel Treatment
79. High-dose tirilazad for acute stroke (RANTTAS II)
80. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS)